98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/DSS.0000000000002396 | DOI Listing |
Perspect Sex Reprod Health
September 2025
Department of Nephrology, Western Health, Victoria, Australia.
Objective: Pregnancy is associated with adverse maternal and fetal outcomes for women with chronic kidney disease (CKD). Yet few women with CKD report receiving information about pregnancy and often experience difficulties making informed childbearing decisions and optimizing pregnancy outcomes. The aim of this study was to identify the fertility and childbearing concerns and related information needs and preferences of women with CKD living in Australia.
View Article and Find Full Text PDFPain Med
September 2025
Department of Wellness and Preventive Medicine, Cleveland Clinic, Cleveland, Ohio, United States.
Patient
September 2025
PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA.
Background: Migraine care is often suboptimal owing to undertreatment, variation in clinical outcomes and administration methods among existing treatments, and between- and within-individual heterogeneity in the clinical course of migraine. In response to these challenges, preference studies have been increasingly conducted to inform treatment decision-making and development. However, gaps remain in understanding how treatment preferences have been assessed across different migraine studies.
View Article and Find Full Text PDFInt J Clin Oncol
September 2025
Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, 305-8575, Japan.
Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.
View Article and Find Full Text PDFSupport Care Cancer
September 2025
Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Purpose: To clarify the preferred timing and contents of early palliative care and preference for continued care delivery among patients with advanced cancer in Japan.
Methods: We conducted an Internet-based anonymous questionnaire survey on adult patients with advanced cancer. We assessed the patients' wishes for palliative care delivered by a team or at outpatient clinics while asymptomatic, as well as the preferred intervention timing and preference for continuing care lifelong.